Navigation Links
UC San Diego researchers receive new CIRM funding
Date:5/25/2012

Five scientists from the University of California, San Diego and its School of Medicine have been awarded almost $12 million in new grants from the California Institute for Regenerative Medicine (CIRM) to conduct stem cell-based research into regenerating spinal cord injuries, repairing gene mutations that cause amyotrophic lateral sclerosis and finding new drugs to treat heart failure and Alzheimer's disease.

The awards mark the third round of funding in CIRM's Early Translational Awards program, which supports projects that are in the initial stages of identifying drugs or cell types that could become disease therapies. More than $69 million in awards were announced yesterday, including funding for first-ever collaboratively funded research projects with China and the federal government of Australia.

"With these new awards, the agency now has 52 projects in 33 diseases at varying stages of working toward clinical trials," said Jonathan Thomas, JD, PhD and CIRM governing board chair. "Californians should take pride in being at the center of this worldwide research leading toward new cures. These projects represent the best of California stem cell science and the best international experts who, together, will bring new therapies for patients."

The five new UC San Diego awards are:

With a $1.8 million award, Lawrence Goldstein, PhD, professor in the Department of Cellular and Molecular Medicine, Howard Hughes Medical Institute Investigator and director of the UC San Diego Stem Cell Program, and colleagues will continue their work developing new methods to find and test drug candidates for Alzheimer's disease (AD). Currently, there is no effective treatment for AD. The researchers screen novel candidates using purified human brain cells made from human reprogrammed stem cells. Already, they have discovered that these human brain cells exhibit a unique biochemical behavior that indicates early development of AD in a dish.

Mark H. Tuszynski, MD, PhD, professor of neurosciences and director of the Center for Neural Repair at UC San Diego, and colleagues seek to develop more potent stem cell-based treatments for spinal cord injuries. By combining grafts of neural stem cells with scaffolds placed at injury sites, the researchers have reported substantial progress in restoring functional improvement in impaired animal models. The new $4.6 million grant will fund work to identify the optimal human neural stem cells for preclinical development and, in an unprecedented step, test this treatment in appropriate preclinical models of spinal cord injury, providing the strongest validation for human translation.

Amyotrophic lateral sclerosis or ALS (Lou Gehrig's disease) is a progressive neurological condition that is currently incurable. Gene Yeo, PhD, assistant professor in the Department of Cellular and Molecular Medicine, and colleagues will use a $1.6 million grant to exploit recent discoveries that specific mutations in RNA-binding proteins cause neuronal dysfunction and death. They will use neurons generated from patient cells containing the mutations to identify the unique RNA "signature" of these doomed neurons and screen for drug-like compounds that bypass the mutations to correct the RNA signature to obtain healthy neurons.

Eric David Adler, MD, an associate clinical professor of medicine and cardiologist, studies heart failure, including the use of stem cells to treat it. His $1.7 million award will fund research into Danon disease, a type of inherited heart failure that frequently kills patients by their 20s. Adler and colleagues will turn stem cells created from skin cells of patients with Danon disease into heart cells, then screen hundreds of thousands of drug candidates for beneficial effects. The most promising drugs will subsequently be tested on mice with a genetic defect similar to Danon disease, with the ultimate goal of identifying a suitable candidate for human clinical trials. The research may have broader applications for other conditions with similar pathogenesis, such as cancer and Parkinson's disease.

Yang Xu, PhD, a professor in the Division of Biological Sciences at UC San Diego, also investigates heart failure, which currently has limited, effective therapeutic options. His grant for $1.8 million will support research into using human embryonic stem cells to produce a renewable source of human cardiomyocytes (heart muscle cells) to replace cells damaged or destroyed by disease. Xu's work will specifically focus upon overcoming immunological resistance to the new cells.


'/>"/>
Contact: Scott LaFee
slafee@ucsd.edu
619-543-6163
University of California - San Diego
Source:Eurekalert

Related medicine news :

1. UC San Diego Superfund Research Program receives $15 million grant renewal
2. UC San Diego among first in nation to treat brain cancer with novel viral vector
3. UC San Diegos William C. Mobley recognized for contributions to Down syndrome
4. AAAS Pacific Division to convene joint session with world mummy scholars in San Diego
5. Study finds Filipino children in San Diego County at higher risk for Kawasaki disease
6. UC San Diego receives 2 major biomedical informatics grants
7. UC San Diego researchers identify factor boosting leukemias aggressiveness
8. La Jolla Institute to develop San Diegos first center for RNAi genomics research
9. UC San Diego partners with Mozambique University to deliver quality health care
10. UC San Diego researcher awarded $3.8 million for new path to breast cancer therapy
11. Type 1 diabetes research at UC San Diego gets $5 million boost
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... ... ... AlignLife clinics nationwide are giving back to their communities by collecting toys during ... wrapped tightly under a Christmas Tree. AlignLife hopes to spread the joy and ... exchange for generous donations, customers will receive a gift in return. Anyone who ...
(Date:12/7/2016)... ... December 07, 2016 , ... The Honolulu cosmetic ... redesigned website, which launched October 17, 2016, features comprehensive information regarding a wide ... layout. Visitors and patients can discover the latest clinical dermatology treatments for medical ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... Campaign Winner in the Folio: Marketing Awards competition. Live From won in the ... in pioneering, inventive, and ultimately successful projects undertaken by the media industry’s most ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... its newest portable bioelectronic medicine device WellnessPro Plus for consumers and healthcare ... enhances the WellnessPro platform by expanding the treatment modalities available in a ...
(Date:12/7/2016)... ... , ... “Walking With God: Inspirational Lessons from My Life's Journey”: a ... aware of God's direction in their lives. “Walking With God: Inspirational Lessons from My ... church leader. , Sanford says, “I enjoy sharing the true stories in ...
Breaking Medicine News(10 mins):
(Date:12/7/2016)... -- Today, Stock-Callers.com presents four Biotech equities for ... Anthera Pharmaceuticals Inc. (NASDAQ: ANTH ), ProNAi Therapeutics ... AVXS ). From its peak in July 2015, ... a level equal to what it saw at the start ... the year, it has still out-performed other market sectors, beating ...
(Date:12/7/2016)...  Lannett Company, Inc. (NYSE: LCI ) today announced ... Prescription for Success Healthcare Conference on December 14, 2016 at 9:20 ... York City . In addition, the company will ... 4 th Annual Boston Healthcare Conference taking place on December ... ...
(Date:12/6/2016)... Dec. 6, 2016  Licenders is bringing their 100% all-natural lice ... in Park Slope at 203 13 th Street was specifically ... clientele. "Our goal is to ease parents, stress ... designed to get children right back to class without skipping a ... natural and safe for the whole family," Licenders President Adie ...
Breaking Medicine Technology: